Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Imidazo[1,2-a]pyrimidines as functionally selective GABA(A) ligands.

Wesley P Blackaby1, John R Atack, Frances Bromidge

  • 1Neuroscience Research Centre, Merck Sharp and Dohme Research Laboratories, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, UK. Wesley_Blackaby@merck.com

Bioorganic & Medicinal Chemistry Letters
|January 13, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Distinct Plasmodium falciparum Erythrocyte Membrane Protein 1 Domain Cassette-Associated Antibody Gaps Specific to Cerebral Malaria and Severe Malarial Anemia.

The Journal of infectious diseases·2026
Same author

Novel positive allosteric modulators of alpha 5 subunit-containing GABA<sub>A</sub> receptors (α5-GABA<sub>A</sub>Rs) reverse the hyperdopaminergic state in a neurodevelopmental model of schizophrenia.

Schizophrenia research·2026
Same author

Negative allosteric modulation of α5-GABA<sub>A</sub> receptors engages dynamic cortical glutamatergic and GABAergic mechanisms underlying adaptive behavior in mice.

bioRxiv : the preprint server for biology·2026
Same author

A PK/PD study on antihyperalgesia by an α2/3-GABA<sub>A</sub> receptor PAM in mice: Lack of tolerance liability and potential involvement of γ1-GABA<sub>A</sub> receptors.

British journal of pharmacology·2026
Same author

Head and neck lymphoedema service provision in the UK: a survey of practice.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2025
Same author

Diffuson-Driven Lattice Thermal Conductivity in Zintl Arsenides: Disrupting Mass-Thermal Conductivity Relation for High Thermoelectric Performance.

Journal of the American Chemical Society·2025

Imidazo[1,2-a]pyrimidines selectively target GABA(A) receptor subtypes. Structure-activity relationship studies optimized this functional selectivity, particularly for the alpha(3) subtype over the alpha(1) subtype.

Area of Science:

  • Medicinal Chemistry
  • Neuropharmacology
  • Drug Discovery

Background:

  • Imidazo[1,2-a]pyrimidines are recognized as ligands for the benzodiazepine binding site on GABA(A) receptors.
  • These compounds have demonstrated potential for subtype-selective interactions, notably favoring the alpha(3) subtype over the alpha(1) subtype.

Purpose of the Study:

  • To conduct Structure-Activity Relationship (SAR) studies on imidazo[1,2-a]pyrimidine derivatives.
  • To optimize compounds for enhanced functional selectivity towards the GABA(A) receptor alpha(3) subtype compared to the alpha(1) subtype.

Main Methods:

  • Systematic chemical modifications of the imidazo[1,2-a]pyrimidine scaffold.
  • Evaluation of ligand binding and functional activity at different GABA(A) receptor subtypes (alpha1, alpha3).

Related Experiment Videos

  • Analysis of SAR to identify key structural features driving subtype selectivity.

    • Main Results:

    • Identification of specific structural modifications that significantly improve functional selectivity for the alpha(3) subtype.
    • Demonstration of optimized imidazo[1,2-a]pyrimidines exhibiting a clear preference for alpha(3) over alpha(1) subtypes.
    • Elucidation of the SAR trends governing this observed selectivity.

    Conclusions:

    • Structure-activity relationship studies are effective in optimizing imidazo[1,2-a]pyrimidines for GABA(A) receptor subtype selectivity.
    • The optimized compounds represent promising leads for developing therapeutics targeting specific GABA(A) receptor subtypes.
    • This work contributes to the development of selective modulators of GABA(A) receptors for potential therapeutic applications.